BKBožo Krušlin

Božo Krušlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Božo Krušlin has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Monika Ulamec

    Clinical Department of Pathology and Cytology "Ljudevit Jurak", Sestre Milosrdnice University Hospital Center, Zagreb, Croatia; Scientific Center of Excellence for Reproductive and Regenerative Medicine, University of Zagreb, School of Medicine, Zagreb, Croatia; Pathology Department, School of Medicine University of Zagreb, Zagreb, Croatia

    4 shared publications
  • Nino Sinčić

    Scientific Centre of Excellence for Reproductive and Regenerative Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

    2 shared publications
  • Alma Demirović

    Department of Pathology and Cytology “Ljudevit Jurak”, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia

    1 shared publication
  • Ana Dunatov Huljev

    Department of Pathology, Forensic Medicine and Cytology, University Hospital of Split, 21000 Split, Croatia

    1 shared publication
  • Ana Fröbe

    Department of Pathology, School of Medicine, University of Zagreb, Zagreb ; Department of Oncology, Sestre Milosrdnice University Hospital Centre, Zagreb

    1 shared publication
  • Ana Katušić Bojanac

    Department of Medical Biology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

    1 shared publication

Latest Publications

  • Open Access

    Tumor-Associated Macrophage Polarization in Wilms’ Tumor After Neoadjuvant Chemotherapy

    by Karolina Malić Tudor, Sandra Zekić Tomaš, Ana Dunatov Huljev, Višnja Armanda Bogdan, Antonela Matana, Marin Ogorevc, Sven Seiwerth, Božo Krušlin, Jasminka Stepan Giljević, Ivana Kuzmić Prusac

    Background/Objectives: Wilms’ tumor (WT) is the most common malignant renal tumor in childhood, and although survival rates are high, a subset of patients with high-risk disease remain prone to treatment resistance and relapse. Increasing evidence suggests that the tumor microenvironment, particularly tumor-associated macrophages (TAMs), may influence tumor behavior and therapeutic response. This study aimed to characterize M1 and M2 macrophage infiltration in WT treated with neoadjuvant chemotherapy according to the International Society of Pediatric Oncology (SIOP) protocol and to evaluate their association with clinicopathological features. Methods: Tumor tissue samples from 46 pediatric patients were analyzed using double immunohistochemical staining for CD80 (M1) and CD163 (M2) macrophages. TAM density and M1/M2 ratios were quantified in viable tumor areas and correlated with clinical, laboratory, and pathohistological parameters. Results: Total TAM counts were significantly higher in tumors with a volume ≥ 500 mL and in unifocal tumors. Both M1 and M2 macrophages were more abundant in larger tumors; however, M2 macrophages predominated overall. The M1/M2 ratio was positively associated with total TAM counts and was significantly higher in tumors with larger volume, elevated serum neuron-specific enolase, and increased creatinine levels. Regressive histological subtypes exhibited a higher M1/M2 ratio compared with other subtypes. No significant associations were observed between macrophage infiltration and tumor stage or risk group. Conclusions: WT treated with neoadjuvant chemotherapy demonstrates low overall macrophage infiltration with a predominance of M2 macrophages. TAM polarization appears to be associated with tumor burden and selected biochemical parameters, highlighting the potential relevance of macrophages as biomarkers and therapeutic targets in WT.

  • Open Access

    PD-L1 expression in testicular germ cell tumors undergoing spontaneous regression

    by Ivan Novak, Miroslav Tomić, Denis Mulabdić, Ivan Pezelj, Slaven Čiček, Igor Tomašković, Nino Sinčić, Božo Krušlin, Monika Ulamec

    Spontaneous regression of testicular germ cell tumors is a well-known phenomenon; however, the precise mechanisms of spontaneous regression are still unknown. Our study aimed to investigate programmed death-ligand 1 (PD-L1) expression in spontaneously regressed testicular germ cell tumors, exploring the link between the immune response and spontaneous regression. From a sample of 356 testicular germ cell tumors, we singled out 5 completely regressed and 6 partially regressed tumors. In four out of six cases with partial regression, a residual seminoma component was found, while in the remaining two cases, an embryonal carcinoma component was found. Comparisons were made with 20 pure seminomas and 20 mixed germ cell tumors (MGCTs). A semiquantitative immunohistochemical analysis of PD-L1 expression in tumor cells and intra/peritumoral lymphocytes was performed. There was no PD-L1 expression in tumors with complete regression. All partially regressed tumors showed expression in intra/peritumoral lymphocytes within the tumor remnants. Expression was significantly more frequent in pure seminomas compared to MGCTs (P = 0.004). A positive correlation was demonstrated between the seminoma component and the proportion of PD-L1 positive lymphocytes, with a Kendall's Tau-b coefficient of 0.626 (P < 0.001). Tumor cells showed PD-L1 expression in three MGCTs within the embryonal carcinoma component. Our results support an immunological mechanism of spontaneous tumor regression, with the strongest potential in testicular tumors containing seminoma components. However, further research is necessary to determine the role of PD-L1 ligand more precisely in the microenvironment of spontaneously regressed tumors.


  • Open Access

    MicroRNA-193a-3p as a Valuable Biomarker for Discriminating between Colorectal Cancer and Colorectal Adenoma Patients

    by Marija Fabijanec, Andrea Hulina-Tomašković, Mario Štefanović, Donatella Verbanac, Ivana Ćelap, Anita Somborac-Bačura, Marija Grdić Rajković, Alma Demirović, Snježana Ramić, Božo Krušlin, et al.

    Specific markers for colorectal cancer (CRC), preceded by colorectal adenoma (pre-CRC), are lacking. This study aimed to investigate whether microRNAs (miR-19a-3p, miR-92a-3p, miR-193a-3p, and miR-210-3p) from tissues and exosomes are potential CRC biomarkers and compare them to existing biomarkers, namely carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9. MiRNA was isolated in the samples of 52 CRC and 76 pre-CRC patients. Expression levels were analyzed by RT-qPCR. When comparing pre-CRC and CRC tissue expression levels, only miR-193a-3p showed statistically significant result (p < 0.0001). When comparing the tissues and exosomes of CRC samples, a statistically significant difference was found for miR-193a-3p (p < 0.0001), miR-19a-3p (p < 0.0001), miR-92a-3p (p = 0.0212), and miR-210-3p (p < 0.0001). A receiver-operating characteristic (ROC) curve and area under the ROC curve (AUC) were used to evaluate the diagnostic value of CEA, CA 19-9, and miRNAs. CEA and CA 19-9 had good diagnostic values (AUCs of 0.798 and 0.668). The diagnostic value only of miR-193a-3p was highlighted (AUC = 0.725). The final logistic regression model, in which we put a combination of CEA concentration and the miR-193a-3p expression level in tissues, showed that using these two markers can distinguish CRC and pre-CRC in 71.3% of cases (AUC = 0.823). MiR-193a-3p from tissues could be a potential CRC biomarker.


  • Open Access

    Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16

    by Robert Terlević, Monika Ulamec, Goran Štimac, Jure Murgić, Božo Krušlin

    The choice of therapy for muscle-invasive bladder cancer (MIBC) could be influenced by the tumor’s molecular subtype. Currently, well-defined consensus subtypes are based on tumor microarray mRNA data. Clearly defined and easy-to-use surrogate molecular subtypes, based on immunohistochemistry (IHC) performed on whole slides, are needed to make subtyping cost-effective and useful in routine work and future research. To aid in the development of a simple immunohistochemical classifier, a retrospective single-center series of 92 cases of localized bladder cancer was identified. Routine IHC for GATA3, cytokeratins 5 and 6 (CK5/6), and p16 was performed on whole tissue blocks containing muscle-invasive disease. Electronic medical records were retrieved and searched for clinical variables, treatment, and survival data. The mean age was 69.6 years, and 73% were males. Conservative treatment was used in 55% of cases, while cystectomy with chemotherapy was used in 45%. GATA3 and CK5/6 expression divided cases into broad luminal and basal subtypes, respectively, while p16 expression was used to subclassify luminal cases into luminal papillary and luminal unstable types according to the consensus molecular classification. When subtyped in this way, GATA3 and CK5/6 negative cases showed worse overall survival. Molecular subtyping of MIBC on whole slides containing muscle-invasive tumor using only three commonly used, consensus-based antibodies, is a feasible and cost-effective method for detecting subtypes of invasive bladder cancer. Future work combining morphological analysis and IHC is needed to fully translate the consensus molecular classification into a comprehensive, cost-effective subtyping strategy.


  • Open Access

    Neglected tuberculous trochanteric bursitis in an adolescent girl: A case report and literature review

    by Josip Vlaic, Ivan Pavic, Ana Tripalo Batos, Ljiljana Zmak, Bozo Kruslin

    Tuberculous trochanteric bursitis (TTB) is an extremely rare form of extrapulmonary tuberculosis. Due to a low clinical suspicion and poor collaboration among medical professionals, the diagnosis of TTB can be often delayed. In this report, we describe a case of neglected TTB in an adolescent girl that initially presented with right thigh swelling and fluctuance. The patient underwent repeated unsuccessful surgical treatment; however, dull pain and periodic wound drainage remained for eight years. Complete excision of fistula and trochanteric bursa and one year of oral antituberculous drug therapy led to complete recovery. This case report highlights tuberculosis as a diagnostic challenge, when rare localizations are affected. In addition, this report addresses several diagnostic pitfalls and reviews the literature regarding TTB in adolescent patients. Orthopedic surgeons need to consider TTB, when swelling, fluctuance or repeated wound drainage are present on the thigh.


  • Open Access

    Genetics of Prostate Carcinoma

    by Božo Krušlin, Lucija Škara, Tonći Vodopić, Borna Vrhovec, Jure Murgić, Goran Štimac, Ana Fröbe, Cvjetko Lež, Monika Ulamec, Koraljka Gall-Trošelj

    The aim of this review is to provide a brief overview of some current approaches regarding diagnostics, pathologic features, treatment, and genetics of prostate carcinoma (PCa). Prostate carcinoma is the most common visceral tumor and the second most common cancer-related cause of death in males. Clinical outcomes for patients with localized prostate cancer are excellent, but despite advances in prostate cancer treatments, castrate-resistant prostate cancer and metastatic prostate cancer patients have a poor prognosis. Advanced large-scale genomic studies revealed a large number of genetic alterations in prostate cancer. The meaning of these alterations needs to be validated in the specific prostate cancer molecular subtype context. Along these lines, there is a critical need for establishing genetically engineered mouse models, which would include speckle type BTB/POZ protein and isocitrate Dehydrogenase (NADP (+)) 1 mutant, as well as androgen receptor neuroendocrine subtypes of prostate cancer. Another urgent need is developing highly metastatic prostate cancer models, as only up to 17% of available models dis- play bone metastases and exhibit a less typical neuroendocrine prostate cancer or sarcomatoid carcinoma. Moreover, androgen deprivation and relapse should be mimicked in the genetically engineered mouse models, as androgen independence may yield a better model for metastatic castrate-resistant prostate cancer. The development of such refined animal models should be guid- ed by comparative genomics of primary versus corresponding metastatic tumors. Such an approach will have the potential to illuminate the key genetic events associated with specific molecular prostate cancer subsets and indicate directions for effective therapy.Conclusion. Despite excellent results in the treatment of localized prostatic carcinoma, castrate-resistant prostate can- cer and metastatic prostate cancer have a poor prognosis. Advanced large-scale genomic studies revealed a large number of ge- netic alterations in PCa. Experimental models of prostate carcinoma in genetically modified mice could provide new data about the genetic changes in such cancers and help in developing better animal models for treatment resistant prostate carcinomas.


  • Open Access

    In Search of TGCT Biomarkers: A Comprehensive In Silico and Histopathological Analysis

    by Dora Raos, Jure Krasic, Silvija Masic, Irena Abramovic, Marijana Coric, Bozo Kruslin, Ana Katusic Bojanac, Floriana Bulic-Jakus, Davor Jezek, Monika Ulamec, et al.

    Testicular germ cell tumors (TGCTs) are ever more affecting the young male population. Germ cell neoplasia in situ (GCNIS) is the origin of TGCTs, namely, seminomas (SE) and a heterogeneous group of nonseminomas (NS) comprising embryonal carcinoma, teratoma, yolk sac tumor, and choriocarcinoma. Response to the treatment and prognosis, especially of NS, depend on precise diagnosis with a necessity for discovery of new biomarkers. We aimed to perform comprehensive in silico analysis at the DNA, RNA, and protein levels of six prospective (HOXA9, MGMT, CFC1, PRSS21, RASSF1A, and MAGEC2) and six known TGCT biomarkers (OCT4, SOX17, SOX2, SALL4, NANOG, and KIT) and assess its congruence with histopathological analysis in all forms of TGCTs. Cancer Hallmarks Analytics Tool, the Search Tool for the Retrieval of Interacting Genes/Proteins database, and UALCAN, an interactive web resource for analyzing cancer OMICS data, were used. In 108 TGCT and 48 tumor-free testicular samples, the immunoreactivity score (IRS) was calculated. SE showed higher frequency in DNA alteration, while DNA methylation was significantly higher for all prospective biomarkers in NS. In GCNIS, we assessed the clinical positivity of RASSF1 and PRSS21 in 52 and 62 of samples, respectively, in contrast to low or nil positivity in healthy seminiferous tubules, TGTCs as a group, SE, NS, or all NS components. Although present in approximately 80 of healthy seminiferous tubules (HT) and GCNIS, HOXA9 was diagnostically positive in 64 of TGCTs, while it was positive in 82 of NS versus 29 of SE. Results at the DNA, mRNA, and protein levels on putative and already known biomarkers were included in the suggested panels that may prove to be important for better diagnostics of various forms of TGCTs.


  • Open Access

    PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PRO STATIC ADENOCARCINOVIA

    by Silvija Masic, Ivan Pezelj, Bozo Kruslin

    Prostatic adenocarcinoma (PC) comprises around 19% of malignancies in Croatian male population. On the basis of PSA value, Gleason score, grading group and clinical stage, PC can be classified into low- and high-risk groups which is significant for different therapeutic regimens and prognostic outcomes. In this retrospective study, we analyzed the difference in preoperative PSA value in a group of 272 patients who underwent radical prostatectomy and were diagnosed with PC adenocarcinoma in our institution in a period from January 1st, 2018 untill December 31st, 2018. Subsequently, they were divided into low- and high-risk prostatic adenocarcinoma groups. Our results demonstrated positive correlation in preoperative PSA values between the groups and therefore support the use of PSA as one of the parameters in defining low- and high-risk prostatic adenocarcinoma categories.


  • Mucinous Cystadenoma Arising in an Isolated Ileal Duplication Cyst

    by Davor Tomas, Mario Zovak, Slaven Čiček, Petra Šulentić, Zoran Jukić, Božo Krušlin

    A 64-year-old woman with a 2-year history of bilateral breast carcinoma with axillary node metastasis and chemotherapy was admitted to our hospital due to tumor attached to the ileum, discovered during the routine control examination. Computerized axial tomography showed oval cystic tumor in terminal ileum that measured 7 cm in the largest diameter and shared peritoneal coat with small intestine and was filled with dense fluid. Tumor abutted intestine but did not communicate with intestinal lumen. The surgical procedure was simple because cyst was attached to the antimesenteric side of the terminal ileum and did not communicate with the adjacent intestine. Pathohistological examination showed mucinous cystadenoma with high-grade epithelial dysplasia in the isolated ileal duplication cyst. The presence of epithelial dysplasia found in duplication cyst suggested potential to undergo malignant transformation. In conclusion, we report a unique case of mucinous cystadenoma arising in isolated ileal duplication cyst. This case report expands the potential range of clinical variability of alimentary tract duplications. Surgical removal of alimentary tract duplication in patients without symptoms is also recommended because many potential complications or even malignant transformation may result from these anomalies.